BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24274863)

  • 1. The impact of obesity on liver histology.
    Goodman ZD
    Clin Liver Dis; 2014 Feb; 18(1):33-40. PubMed ID: 24274863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A; Hellerbrand C
    Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver pathology in obesity.
    Suriawinata A; Fiel MI
    Semin Liver Dis; 2004 Nov; 24(4):363-70. PubMed ID: 15605304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Patomechanisms of hepatic steatosis].
    Fülöp P; Paragh G
    Orv Hetil; 2010 Feb; 151(9):323-9. PubMed ID: 20159747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):289-94. PubMed ID: 15730035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.
    Lackner C
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):223-31. PubMed ID: 21476917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma.
    Singhi AD; Jain D; Kakar S; Wu TT; Yeh MM; Torbenson M
    Am J Surg Pathol; 2012 May; 36(5):710-5. PubMed ID: 22498821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
    Sanyal AJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steatosis: co-factor in other liver diseases.
    Powell EE; Jonsson JR; Clouston AD
    Hepatology; 2005 Jul; 42(1):5-13. PubMed ID: 15962320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?
    Machado MV; Cortez-Pinto H
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):213-22. PubMed ID: 21476916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver pathology and the metabolic syndrome X in severe obesity.
    Marceau P; Biron S; Hould FS; Marceau S; Simard S; Thung SN; Kral JG
    J Clin Endocrinol Metab; 1999 May; 84(5):1513-7. PubMed ID: 10323371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is non alcoholic steatohepatitis (NASH) part of the metabolic syndrome?].
    Fehér J; Németh E; Lengyel G
    Orv Hetil; 2004 Jul; 145(29):1499-506. PubMed ID: 15453020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
    Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
    J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment.
    Rahimi RS; Landaverde C
    Nutr Clin Pract; 2013 Feb; 28(1):40-51. PubMed ID: 23286927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
    Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y
    Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.